Formulations and Product Development

Develop Solid and Liquid Formulations With Desired Disintegration and Dissolution Profiles

Ring för offert

The particle size distribution is one of the most critical parameters in drug product quality. Real time understanding and control of particles ensures Quality by Design (QbD) in solid and liquid dosage formulation. FBRM® and PVM® Process Analytical Technologies (PAT) provide in-process real time measurements of particle dimension, particle shape, and particle count. FBRM® and PVM® are used to promote faster formulation development, improve process confidence, and control batch-to-batch consistency.
  • Dissolution Testing - FBRM® tracks tablet, capsule, and granule disintegration and dissolution mechanisms in real time to uncover the root cause of dissolution performance inconsistencies
  • Granulation - FBRM® and PVM® provide immediate feedback for batch control and repeatability, without the need for offline sampling.  Optimize granulation development and scale-up by directly monitoring the granule distribution in real time
  • Fluid Bed - FBRM® and PVM® detect and control attrition, breakage, and agglomeration in the fluid bed.  Ensure a repeatable endpoint particle size distribution
  • Milling - Monitor the real-time particle distribution at the outlet of the mill to further control batch repeatability
  • Liquid Suspensions - Ensure particle stability and homogeneity by tracking the particle distribution in real time

After purchasing Lasentec® in 2001, METTLER TOLEDO has become the world leader for in-line particle/droplet size, shape, and count characterization.

Formulations and Product Development
Formulations and Product Development

Applikationer

Tablet Disintegration and Dissolution
Solid Oral Dosage Form Development

Role of PEG-Lipid Nanoparticles in the Development of mRNA Vaccines
Automated Solutions and In-Situ PAT to Support LNP Formulation

Learn how automated lab reactors and in-situ PAT enabled rapid process scale-up of PEG-lipid nanoparticle (LNP) formulation for mRNA vaccines during the COVID-19 pandemic.

Role of PEG-Lipid Nanoparticles in the Development of mRNA Vaccines

Learn how automated lab reactors and in-situ PAT enabled rapid process scale-up of PEG-lipid nanoparticle (LNP) formulation for mRNA vaccines during the COVID-19 pandemic.

Trycksaker

Relaterade produkter